Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Filed Chapter 11
Quarterly results
Appointed director
OSCIENT PHARMACEUTICALS CORP (OSCI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/25/2009 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results - Conference call scheduled for Thursday, March 26 at 8:30 AM ET -",
"NASDAQ Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to October 6, 2009"
11/04/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results — Total revenues increase more than 40% from Q3 2007 — - Conference call with senior management scheduled for 8:30 AM today -"
08/01/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Second Quarter 2008 Financial Results — Total revenues increase 27% from Q2 2007 — — Conference call with senior management scheduled for 8:30 AM today"
05/07/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports First Quarter 2008 Financial Results — Conference call with senior management scheduled for 8:30 AM today",
"Regulatory Filing for FACTIVE Tablets Submitted in Europe — Oscient Pharmaceuticals' partner, Menarini Group, seeks marketing approval for fluoroquinolone antibiotic"
02/06/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Records 2007 Revenues of $80 Million; Reports Financial Results for Fourth Quarter and Fiscal Year 2007 — Conference call with senior management scheduled for 8:30 AM today"
10/31/2007 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Financial Results for Third Quarter 2007 — Total revenues increase more than 25% over Q3 2006; Nine-month revenues increase 96% from prior year reflecting ANTARA acquisition — - Conference call with senior management scheduled for 8:30 AM ET today -"
08/03/2007 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Financial Results for Second Quarter 2007 — Total revenues increase approximately 250% over Q2 2006 reflecting ANTARA acquisition; ANTARA revenues increase 14% from prior quarter — - Conference call with senior management scheduled for 8:30 AM ET today -"
05/04/2007 8-K Quarterly results
Docs: "Indenture between Oscient Pharmaceuticals Corporation and U.S. Trust National Association, as Trustee",
"Oscient Pharmaceuticals Reports Financial Results for First Quarter 2007 — Total revenues increase 110% over Q1 2006 reflecting ANTARA acquisition — - Conference call with senior management scheduled for 8:30 AM ET today -",
"FDA Approves Oscient Pharmaceuticals' FACTIVE Tablets for Five-Day Treatment of Community-Acquired Pneumonia — Only fluoroquinolone approved in the U.S. for five-day treatment of both CAP and AECB — Waltham, MA, May 2, 2007 - The U.S. Food and Drug Administration has approved Oscient Pharmaceuticals' FACTIVE tablets for the five-day treatment of community-acquired pneumonia of mild to moderate severity . The approved supplemental New Drug Application was based on the results of the Company's successful Phase III trial in 510 CAP patients comparing a five-day treatment and the originally approved seven-day treatment with FACTIVE 320 mg once-daily. Oscient first launched FACTIVE for the seven-day treatment of CAP and the five-day treatment of acute bacterial exacerbations of chronic bronchit..."
02/28/2007 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Financial Results for Fourth Quarter and Fiscal Year 2006 — Total revenues increase 95% in 2006 reflecting ANTARA acquisition — - Conference call with senior management scheduled for 8:30 AM ET today -"
11/09/2006 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Financial Results for Third Quarter of 2006 —Revenue growth of 110% over Q3 2005 reflects ANTARA acquisition— — Conference call with senior management scheduled for 8:30 AM ET today"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy